Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217
Although all plasma p-tau measurements enabled discrimination between clinical groups, p-tau217 assays showed the highest robustness, independently of the pan-tau detector antibody targeting N-terminal or mid-region, and independently of the platform used. Considering the observed method disagreement in measured absolute concentrations, we stress the need for development of certified reference material, harmonizing measurements across different platforms.
Authors
- Sherif Bayoumy (ORCID: https://orcid.org/0000-0002-3480-5136)
- Manu Vandijck
- Wiesje M. van der Flier (ORCID: https://orcid.org/0000-0001-8766-6224)
- Erik Stoops (ORCID: https://orcid.org/0000-0001-9989-4486)
- Jeroen Vanbrabant
- Daniel Antwi‐Berko (ORCID: https://orcid.org/0000-0001-8994-1349)
- Nathalie Le Bastard (ORCID: https://orcid.org/0000-0002-7981-2866)
- Charlotte Lambrechts (ORCID: https://orcid.org/0009-0007-6720-0727)
- Inge M.W. Verberk (ORCID: https://orcid.org/0000-0003-0341-7445)
- Andreas Jeromin
- Charlotte Elisabeth Teunissen (ORCID: https://orcid.org/0000-0002-4061-0837)
- Anna Lidia Wojdała (ORCID: https://orcid.org/0000-0002-6958-8223)
- Maxime Van Loo
Institutions
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- ADx NeuroSciences (BE)
- ADx NeuroSciences
- Fujirebio (Belgium) (BE)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1186/s13195-024-01630-5
- Citations
- 16
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.22
Funders
- Amsterdam University Medical Centers
- European Commission
- ZonMw
- Hersenstichting
- Alzheimer Nederland
- Amsterdam Neuroscience